MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value

$1.19+0.09 (+8.18%)

Close on Nov 12, 2026Market cap $122.82MP/E –Yield –

MaxCyte operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

MaxCyte's operating cash flow for the twelve months ending Sep 30, 2026 was -$21.03M. For fiscal 2025 it was -$34.41M. The highest annual figure on record is -$8.78M in fiscal 2020.

Annual operating cash flow

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$34.41M	–
FY2024	Dec 31, 2024	-$27.61M	–
FY2023	Dec 31, 2023	-$21.69M	–
FY2022	Dec 31, 2022	-$14.78M	–
FY2021	Dec 31, 2021	-$10.68M	–
FY2020	Dec 31, 2020	-$8.78M	–
FY2019	Dec 31, 2019	-$8.80M	–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$5.51M	–
Q2 FY2026	Jun 30, 2026	-$4.66M	–
Q1 FY2026	Mar 31, 2026	-$8.17M	–
Q4 FY2025	Dec 31, 2025	-$2.69M	–
Q3 FY2025	Sep 30, 2025	-$7.46M	–
Q2 FY2025	Jun 30, 2025	-$9.85M	–
Q1 FY2025	Mar 31, 2025	-$14.41M	–
Q4 FY2024	Dec 31, 2024	-$7.82M	-897.2%
Q3 FY2024	Sep 30, 2024	-$4.39M	–
Q2 FY2024	Jun 30, 2024	-$4.83M	–
Q1 FY2024	Mar 31, 2024	-$10.56M	–
Q4 FY2023	Dec 31, 2023	$981.00K	–
Q3 FY2023	Sep 30, 2023	-$8.24M	–
Q2 FY2023	Jun 30, 2023	-$10.11M	-1200.0%
Q1 FY2023	Mar 31, 2023	-$4.32M	–
Q4 FY2022	Dec 31, 2022	-$6.09M	–
Q3 FY2022	Sep 30, 2022	-$5.92M	–
Q2 FY2022	Jun 30, 2022	$918.60K	–
Q1 FY2022	Mar 31, 2022	-$3.69M	–
Q4 FY2021	Dec 31, 2021	-$960.25K	–
Q3 FY2021	Sep 30, 2021	-$690.45K	–
Q2 FY2021	Jun 30, 2021	-$4.39M	–
Q1 FY2021	Mar 31, 2021	-$4.64M	–
Q4 FY2020	Dec 31, 2020	-$1.91M	–
Q3 FY2020	Sep 30, 2020	-$830.30K	–